Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 285

1.

Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.

Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, Wiznia AA; Pediatric AIDS Clinical Trials Group 377 Study Team.

Pediatr Infect Dis J. 2005 Apr;24(4):352-7.

PMID:
15818296
[PubMed - indexed for MEDLINE]
2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
[PubMed - indexed for MEDLINE]
3.

Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.

Nachman SA, Lindsey JC, Pelton S, Mofenson L, McIntosh K, Wiznia A, Stanley K, Yogev R.

Arch Pediatr Adolesc Med. 2002 May;156(5):497-503.

PMID:
11980557
[PubMed - indexed for MEDLINE]
4.

Impact on weight and height with the use of HAART in HIV-infected children.

Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA.

Pediatr Infect Dis J. 2007 Apr;26(4):334-8.

PMID:
17414398
[PubMed - indexed for MEDLINE]
5.

Height, weight, and growth in children born to mothers with HIV-1 infection in Europe.

Newell ML, Borja MC, Peckham C; European Collaborative Study.

Pediatrics. 2003 Jan;111(1):e52-60.

PMID:
12509595
[PubMed - indexed for MEDLINE]
6.

Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.

Van Rossum AM, Gaakeer MI, Verweel S, Hartwig NG, Wolfs TF, Geelen SP, Lamberts SW, de Groot R.

Pediatr Infect Dis J. 2003 Jan;22(1):70-6.

PMID:
12544412
[PubMed - indexed for MEDLINE]
7.

The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.

Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL.

Pediatrics. 2001 May;107(5):E77.

PMID:
11331727
[PubMed - indexed for MEDLINE]
8.

Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.

Musoke PM, Mudiope P, Barlow-Mosha LN, Ajuna P, Bagenda D, Mubiru MM, Tylleskar T, Fowler MG.

BMC Pediatr. 2010 Aug 6;10:56. doi: 10.1186/1471-2431-10-56.

PMID:
20691045
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

Buchacz K, Cervia JS, Lindsey JC, Hughes MD, Seage GR 3rd, Dankner WM, Oleske JM, Moye J.

Pediatrics. 2001 Oct;108(4):E72.

PMID:
11581480
[PubMed - indexed for MEDLINE]
10.

Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda.

Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW.

AIDS Patient Care STDS. 2008 Mar;22(3):245-51. doi: 10.1089/apc.2007.0049.

PMID:
18298315
[PubMed - indexed for MEDLINE]
11.

Predictors of bone mineral density in human immunodeficiency virus-1 infected children.

Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Miller TL.

J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):339-46.

PMID:
16131991
[PubMed - indexed for MEDLINE]
12.

Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection.

Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE Jr; Pediatric AIDS Clinical Trials Group Protocol 152 Study Team.

Pediatr Infect Dis J. 2003 Dec;22(12):1033-9.

PMID:
14688560
[PubMed - indexed for MEDLINE]
13.

Insulin-like growth factor-1 and lean body mass in HIV-infected children.

Chantry CJ, Hughes MD, Alvero C, Cervia JS, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):437-43. doi: 10.1097/QAI.0b013e31817bbe6d.

PMID:
18614924
[PubMed - indexed for MEDLINE]
14.

Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.

Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, Blanche S, Msellati P.

AIDS. 2004 Sep 24;18(14):1905-13.

PMID:
15353976
[PubMed - indexed for MEDLINE]
15.

Impact of HAART on growth and hospitalization rates among HIV-infected children.

Diniz LM, Maia MM, Camargos LS, Amaral LC, Goulart EM, Pinto JA.

J Pediatr (Rio J). 2011 Mar-Apr;87(2):131-7. doi: doi:10.2223/JPED.2064. Epub 2011 Mar 16. English, Portuguese.

PMID:
21412567
[PubMed - indexed for MEDLINE]
Free Article
16.

Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study.

Miller TL, Easley KA, Zhang W, Orav EJ, Bier DM, Luder E, Ting A, Shearer WT, Vargas JH, Lipshultz SE; Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group; National Heart, Lung, and Blood Institute, Bethesda, MD.

Pediatrics. 2001 Dec;108(6):1287-96.

PMID:
11731650
[PubMed - indexed for MEDLINE]
17.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.

Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.

Pediatrics. 2007 Oct;120(4):e856-61. Epub 2007 Sep 10.

PMID:
17846147
[PubMed - indexed for MEDLINE]
Free Article
18.

The influence of nutritional status on the response to HAART in HIV-infected children in South Africa.

Naidoo R, Rennert W, Lung A, Naidoo K, McKerrow N.

Pediatr Infect Dis J. 2010 Jun;29(6):511-3. doi: 10.1097/INF.0b013e3181d1e989.

PMID:
20179664
[PubMed - indexed for MEDLINE]
19.

Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team.

Pediatr Infect Dis J. 2005 Sep;24(9):793-800.

PMID:
16148846
[PubMed - indexed for MEDLINE]
20.

Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.

Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A; Spanish Group of Paediatric HIV Infection.

Clin Infect Dis. 2006 Mar 15;42(6):862-9. Epub 2006 Feb 9.

PMID:
16477566
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk